However, when RBMS1 is depleted, it destabilizes B4GALT1 transcript, resulting in the suppression of glycosylation and increased degradation of PD-L1, thus promoting anti-tumor T-cell immunity and sensitizing TNBC cells to anti-CTLA4 therapy (Fig. 8D). This evidence concerns the gene CD274 and neoplasm.